Pharmaceutical companies Mylan (NAS: MYL) and Watson Pharmaceuticals (NYS: WPI) have announced that they have received FDA approval for generic versions of Pfizer's (NYS: PFE) Revatio, a drug used to ...
An attempt by Pfizer to extend the uses of its pulmonary artery hypertension (PAH) drug Revatio into a new paediatric indication has had a major setback. Revatio (sildenafil citrate) – which is based ...
Another drug in Pfizer’s (PFE) portfolio started facing generic competition recently. Generic competition for Pfizer’s pulmonary arterial hypertension (:PAH) drug, Revatio (sildenafil) tablets has ...
Sildenafil 10mg/mL; pwd for oral susp after reconstitution; grape flavor; contains sorbitol. Pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay ...
PARSIPPANY, N.J. (AP) -- Watson Pharmaceuticals Inc. said Monday it received approval to sell a generic version of Pfizer Inc.'s drug Revatio, a treatment for pulmonary arterial hypertension. Watson ...
Please provide your email address to receive an email when new articles are posted on . The FDA today released a statement clarifying its previous recommendation related to the prescription of ...
The FDA announced clarifications to its previous recommendation related to prescribing Revatio (sildenafil; Pfizer) for children with pulmonary arterial hypertension (PAH). In August 2012, the Revatio ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. announced that Revatio ® (sildenafil citrate) has been approved by the European Commission for the treatment of pediatric patients aged 1 to 17 years old with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results